Full Press Release Details
Concord Healthcare Announces Completion of China's
First Proton Therapy for Choroidal Malignant Melanoma
BEIJING, July 14, 2025 /PRNewswire/ -- Concord Healthcare
Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company")
(NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the
stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully
completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma.
Choroidal malignant melanoma is a common intraocular malignancy. The
traditional standard treatment is enucleation, i.e. eye removal. Although enucleation can effectively control the local lesion, it will
inevitably lead to permanent blindness and facial appearance changes in patients, and there are still life-threatening risks.
Guangzhou Concord Cancer Center utilizes advanced pencil beam scanning
proton therapy in combination with real-time image guidance system to achieve high-dose and accurate irradiation of target area, while
maximizing the protection of important neighboring structures and allowing the patient to avoid enucleation. As the first medical institution
in China to offer proton therapy for this condition, Guangzhou Concord Cancer Center has filled a critical gap in the field and provided
a new eye-preserving treatment option for patients with choroidal malignant melanoma.
The Company previously announced the listing of Concord Healthcare's
H shares on the HKSE on January 9, 2024. The information related to Concord Healthcare's Transactions on the HKSE is accessible
through the HKSE's website at www.hkexnews.hk.
About Concord Medical
Concord Medical Services Holdings Limited is a healthcare provider
featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses
on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with
technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality
and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China.
For more information, please see http://ir.ccm.cn.
About Concord Healthcare
Concord Healthcare is an oncology healthcare provider in China. Concord
Healthcare serves both cancer patients through self-owned medical institutions and third-party medical institutions through medical
equipment, software and related services. In its self-owned medical institutions, Concord Healthcare provides a full spectrum of oncology
healthcare services to cancer patients across the entire care continuum, leveraging its multidisciplinary team specialists and diagnosis
and treatment capabilities featuring precision radiation therapy. Through its medical equipment, software and related services, Concord
Healthcare serves a widespread network of enterprise customers, primarily hospitals, with integrated oncology-related services, including
primarily sales and installing of medical equipment and software, management and technical support, and operating lease.
Safe Harbor Statement
This announcement contains forward-looking statements. These forward-looking
statements can be identified by words or phrases such as "will," "expects," "anticipates," "future,"
"intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements
are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future
business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those
contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except
as required under applicable law.
For more information, please contact:
Concord Medical Services Holdings Limited